Gut-microbiome-derived metabolite fact sheet
Urolithin A
Also known as UA, pomegranate-derived postbiotic
Urolithin A is produced from dietary ellagitannins by some gut microbiomes. Sponsored trials report mitochondrial biomarker and selected muscle signals, while key primary outcomes have not always improved.
Quick answer
Urolithin A has early human evidence for target engagement and selected muscle-endurance outcomes, but it is not an FDA-approved drug for aging, muscle loss, mitochondrial disease, or immune decline. Trials have been small and commonly industry sponsored.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Urolithin A?
Urolithin A is a metabolite made when certain gut bacteria process ellagitannins found in foods such as pomegranates and walnuts.
It is studied as a trigger of mitophagy, the cellular process that removes damaged mitochondria.
Why are people interested in it?
Mitochondrial quality control is relevant to aging, muscle function, and immune-cell biology.
Human studies provide a stronger translational base than many frontier compounds, but sponsor involvement, modest samples, and mixed endpoints call for independent replication.
Current regulatory status
Urolithin A is not an FDA-approved drug for any aging, muscle, mitochondrial, or immune indication. Supplement availability is not evidence of FDA-reviewed effectiveness.
What is it approved for?
No FDA-approved use. Commercial availability, supplement marketing, and clinical research do not equal an FDA-approved medicine.
What is it being studied for?
Evidence snapshot
Randomized human studies show biochemical target engagement and some secondary muscle or immune signals. In one older-adult trial, the primary walking-distance and ATP-production outcomes were not significantly better than placebo.
Potential benefits being researched
- A controlled older-adult trial reported better muscle endurance and biomarker changes but did not improve its primary walking-distance or ATP-production outcomes over placebo.
- Other sponsored trials report muscle-performance or immune-cell signals that need confirmation in larger independent studies.
A mechanism, biomarker, or secondary endpoint is not proof of a meaningful clinical benefit.
Known or possible risks
- Short trials generally reported similar adverse-event rates to placebo, but sample sizes were too small to define uncommon harms.
- Several pivotal human studies involved the ingredient developer or sponsor, a conflict that does not invalidate results but increases the value of independent replication.
- Commercial supplement quality may not match trial material.
What we still do not know
- Whether effects persist or translate into less disability or disease
- Whether independent trials reproduce sponsor-linked findings
- Long-term safety across diverse populations
- Which people, if any, have a clinically meaningful response
Plain-English takeaway
Urolithin A has promising early human work, but mixed endpoints and a sponsor-heavy evidence base make it a research candidate—not a proven anti-aging therapy.
Research and reference links
Use these primary and authoritative sources to verify status and read beyond this summary. A study or registry entry does not by itself prove benefit.
- 1Randomized urolithin A trial in older adults
Trial with negative primary walking and ATP outcomes but positive muscle-endurance and biomarker findings.
- 2Randomized trial in middle-aged adults
Industry-sponsored study of muscle performance and mitochondrial biomarkers.
- 3First-in-human urolithin A study
Early study establishing bioavailability, short-term tolerability, and biomarker effects.
- 4FDA: what ‘FDA approved’ does and does not mean
FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.